GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » EV-to-FCF

Northwest Biotherapeutics (LTS:0K95) EV-to-FCF : -10.03 (As of May. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Northwest Biotherapeutics's Enterprise Value is £455.51 Mil. Northwest Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was £-45.39 Mil. Therefore, Northwest Biotherapeutics's EV-to-FCF for today is -10.03.

The historical rank and industry rank for Northwest Biotherapeutics's EV-to-FCF or its related term are showing as below:

LTS:0K95' s EV-to-FCF Range Over the Past 10 Years
Min: -47.67   Med: -6.35   Max: -0.69
Current: -10.12

During the past 13 years, the highest EV-to-FCF of Northwest Biotherapeutics was -0.69. The lowest was -47.67. And the median was -6.35.

LTS:0K95's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs LTS:0K95: -10.12

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Northwest Biotherapeutics's stock price is £2.40. Northwest Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was £-0.056. Therefore, Northwest Biotherapeutics's PE Ratio for today is At Loss.


Northwest Biotherapeutics EV-to-FCF Historical Data

The historical data trend for Northwest Biotherapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics EV-to-FCF Chart

Northwest Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.55 -32.94 -15.50 -15.40 -15.20

Northwest Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.71 -12.57 -21.16 -15.20 -11.67

Competitive Comparison of Northwest Biotherapeutics's EV-to-FCF

For the Biotechnology subindustry, Northwest Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's EV-to-FCF falls into.



Northwest Biotherapeutics EV-to-FCF Calculation

Northwest Biotherapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=455.513/-45.393
=-10.03

Northwest Biotherapeutics's current Enterprise Value is £455.51 Mil.
Northwest Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £-45.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Northwest Biotherapeutics  (LTS:0K95) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Northwest Biotherapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.40/-0.056
=At Loss

Northwest Biotherapeutics's share price for today is £2.40.
Northwest Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £-0.056.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Northwest Biotherapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Northwest Biotherapeutics (LTS:0K95) Business Description

Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines